Actually they are both in the same market being; Personal use Medical Devices.
It is a pitty that people run for the mod button instead of actually challenging my argument that RAP is still grossly overprices as compared to *** (the name of which I cannot say because some poor little flower will get upset)
An important part of stock analysis is to compare like for like companies.
Can someone please explain why RAP holds a market cap circa three times that of *** ?
Argue your case instead of running for a mod button.
Compare the two companies (or even like for like companies) and exhibit some analysis skills. Because RAP compared to its peers is still overly priced and its last double blind results still indicate poor performance in addition to RAP only being at a conceptual stage.
- Forums
- ASX - By Stock
- RAP
- Ann: Positive Results from Australian Adult Clinical Studies
Ann: Positive Results from Australian Adult Clinical Studies, page-41
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)